Frank W Murano, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 1101 Richmond Ave Ste 104, Point Pleasant Beach, NJ 08742 Phone: 732-859-4031 |
Ms. Cheryl A. Daniel, L.C.S.W. Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 516 Bay Ave, Point Pleasant Beach, NJ 08742 Phone: 732-714-1830 Fax: 732-714-7842 |
Lisa Ann Verni, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 705 Atlantic Ave, Point Pleasant Beach, NJ 08742 Phone: 732-714-0997 |
Mrs. Gail Marie Poverman-kave, MSW, ACSW, BCD, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 1101 Richmond Ave Ste 203, Point Pleasant Beach, NJ 08742 Phone: 732-223-9898 |
Mrs. Melissa Ann Nagel, MSW, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 803 Grove St, Point Pleasant Beach, NJ 08742 Phone: 732-996-3465 |
News Archive
Human embryonic stem (ES) cells and adult cells reprogrammed to an embryonic stem cell-like state-so-called induced pluripotent stem or iPS cells-exhibit very few differences in their gene expression signatures and are nearly indistinguishable in their chromatin state, according to Whitehead Institute researchers.The pluripotency of ES cells fueled excitement over their use in regenerative medicine. While ethical hurdles associated with the clinical application of human ES cells appeared to have been overcome with the development of methods to create iPS cells, some recent research has suggested that ES and iPS cells have substantial differences in which sets of genes they express.
Australian and New Zealand researchers have accelerated research into Multiple Sclerosis by discovering two new locations of genes which will help to unravel the causes of MS and other autoimmune disease.
Health Officials are still investigating other suspected cases which have been reported in the same area of a West Javanese province.
Insilico Medicine has announced that it has entered into a research collaboration agreement with Astellas Pharma Inc. to utilize Insilico Medicine's novel generative artificial intelligence technology aimed at accelerating development of candidates against a conventionally challenging target family.
› Verified 9 days ago